The Scott Partnership Selected as Agency of Record by Sage-N Research
News May 13, 2010
B2B PR agency The Scott Partnership announces that it has been appointed by San Jose, California-based Sage-N Research, a proteomics data analysis solutions provider and developer of proprietary SEQUEST 3G and Sorcerer 2 solutions, to lead a global PR campaign aimed at increasing visibility of Sage-N Research in the scientific community as a leader in Computational Proteomics Platforms.
The Scott Partnership was appointed as agency of record due to its specialist experience in delivering successful PR campaigns for companies working within mass spectrometry, proteomics, informatics and life science.
With the ability to support campaigns in North America, China and Europe through its strategically placed offices, The Scott Partnership will use its expertise and hands-on approach in building company and brand awareness across multiple geographies to develop and manage a global PR campaign articulating Sage-N Research's global platform in protein discovery.
Sage-N Research is easy to use Integrated Data Appliances (IDA's) for mass spectrometry and proteomic research. Specializing in appliances designed to fully characterize proteins in complex biological samples, Sage-N Research is dedicated to developing a platform for the protein-based translational research, including biomarkers, molecular profiling, and target discovery. Through its next generation software for translational proteomics research, Sage-N Research is helping to accelerate the pace of drug discovery in cancer and stem cell research.
Protein "Intentionally" Terminates own Synthesis by Destabilizing Synthesis Machinery — the RibosomeNews
A research group has discovered that a protein, during its synthesis, may destabilize the structure of the ribosome and end its own synthesis prematurely, and found that this phenomenon is used for adapting the cell to its environment.READ MORE
Pre-Diabetes Discovery Marks Step Towards Precision MedicineNews
Identification of three molecules that can be used to accurately assess pre-diabetes – a key predictor of conditions such as diabetes and high blood pressure – has brought precision medicine for humans a step closer.READ MORE